Monoclonal Antibodies Market Scope
Antibodies, also known as immunoglobulins, are Y-shaped proteins that recognize and neutralize the antigens of invading microbes. The effectiveness of our immune system is determined by how quickly and effectively such antibodies are produced. However, antigen-antibody reactions can be beneficial or harmful. It is not always possible, however, to wait for the body's immune system to produce effective antibodies. As in the case of an epidemic or pandemic, the disease may spread quickly, seriously affecting one or more organs, and multiple lives may be lost. When people who were infected with a specific virus or bacteria did not develop severe symptoms, it indicates that their immune system produced antibodies that were effective in combating the microbe's antigens. Antibodies can be found in their bodies up to 5 or 7 months after infection. These antibodies can be injected into a patient's body if they are carefully extracted or harvested from their body and then replicated or 'cloned' in a laboratory. The patient's body now has the antibodies needed to combat the antigens of the invader. Monoclonal Antibodies, or MABs, are antibodies that have been cloned or duplicated. Unlike MABs, vaccines aim to stimulate the immune system to produce antibodies that are effective in combating the foreign antigen MAB is an inorganic approach, whereas vaccine is an organic one. Monoclonal antibodies are a type of protein that can bind to specific targets in the body, such as antigens on the surface of cancer cells. There are various types of monoclonal antibodies, and each monoclonal antibody is designed to bind to a single antigen. Many diseases, including some types of cancer, are being diagnosed and treated with monoclonal antibodies. They can be used alone or in conjunction with other agents to deliver drugs, toxins, or radioactive substances directly to cancer cells.
|Unit||Value (USD Million)|
|Key Companies Profiled||Novartis AG (Switzerland), Pfizer, Inc. (United States), AstraZeneca (United Kingdom), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson Services, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen, Inc. (United States), Merck & Co., Inc (United States), Daiichi Sankyo Company, Ltd. (Japan) and Novo Nordisk A/S (Denmark)|
The market has seen a massive investment in R&D and product development which has driven the market growth. Massive investments and partnerships to establish a more significant product have helped to grab more markets for key players. The significant response shown in treatments of diseases like cancer has been driving the market. Hospitals have started preferring the treatment over others as this is cost-effective and reliable. This has made new entrances grab a good position in the market. Whereas the big players have tried to develop by mergers and acquisitions and investments in developing better technology to keep up with the competition and hold a higher position in the market. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Monoclonal Antibodies market throughout the predicted period.
Novartis AG (Switzerland), Pfizer, Inc. (United States), AstraZeneca (United Kingdom), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson Services, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen, Inc. (United States), Merck & Co., Inc (United States), Daiichi Sankyo Company, Ltd. (Japan) and Novo Nordisk A/S (Denmark) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Abbott (United States), Eli Lilly (United States), Bayer AG (United States), Bristol Myers Squibb Co. (United States), Mylan N.V. (United States), Biogen Inc. (United States), Thermo Fisher Scientific, Inc. (United States) and Sanofi Genzyme (France).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
The study have segmented the market of Global Monoclonal Antibodies market by Type , by Application (Cancer, Rheumatoid arthritis, Multiple sclerosis, Cardiovascular disease, Systemic lupus erythematosus, Crohn's disease and Other) and Region with country level break-up.
On the basis of geography, the market of Monoclonal Antibodies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2020.
Market Leaders and their expansionary development strategiesIn January 2021 Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fcγ R on macrophages.
In June 2022 Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34% (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001).1 In collaboration with BeiGene, these data were presented today during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (Abstract #LBA-1).
Since November 2020, the U.S. Food and Drug Administration (FDA) has issued several emergency use authorizations (EUAs) to permit the emergency use of investigational monoclonal antibody (mAb) therapies for the treatment of mild to moderate COVID-19 in adult and pediatric patients. Currently authorized mAbs are:, Bebtelovimab (Lilly) EUA issued Feb. 11, 20221 and Bebtelovimab is authorized for use in pediatric patients with positive results from direct SARS-CoV-2 viral testing and who are ages 12 to 17, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. In addition, bebtelovimab is authorized only for people “for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.”
Monoclonal Antibodies Market Dynamics:
|Trends Influencing Market|
- The shift in Preference for Cost-Effective Treatments has Been Showing a Trending Impact on Monoclonal Antibodies Market.
- Alternative Treatment Methods.
- Poor Demand in Underdeveloped Economies.
- Higher Investments and Strategic Partnerships for Further Research and Development by Leading Companies.
- Positive Results of Implementation of Monoclonal Antibodies Treatment for Covid-19 has Opened Many Opportunities.
Key Target AudiencePharmaceutical companies, New Entrants and Investors, Legalized Cannabis Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others